---
title: "Supply of Aseptically Prepared Dose Banded Medicines"
ocid: "ocds-h6vhtk-0308cd"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-0308cd"
markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-0308cd.md"
json_url: "https://d3tenders.com/contract/ocds-h6vhtk-0308cd.json"
source: "Find A Tender Service"
current_stage: "Award"
buyer: "HEALTHTRUST EUROPE LLP (HTE) ACTING AS AGENT FOR THE UNIVERSITY HOSPITALS OF COVENTRY AND WARWICKSHIRE NHS TRUST (“UHCW”)"
published: "2022-07-13"
---

# Supply of Aseptically Prepared Dose Banded Medicines

Buyer: HEALTHTRUST EUROPE LLP (HTE) ACTING AS AGENT FOR THE UNIVERSITY HOSPITALS OF COVENTRY AND WARWICKSHIRE NHS TRUST (“UHCW”)  
Current stage: Award  
OCID: ocds-h6vhtk-0308cd

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-0308cd)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-0308cd.json)

## Summary

The procurement process involves HealthTrust Europe LLP acting as the buying organisation, focusing on the supply of aseptically prepared dose banded medicines, classified under the pharmaceutical products category. This tender, initiated on 1st July 2022, is at the Award stage and includes various lots, each with a two-year initial agreement period and the possibility of two additional years of extension. The tender is based in the UK and employs an open procedure for procurement, ensuring a fair and competitive bidding process.

This tender presents significant opportunities for businesses, particularly those specialising in pharmaceutical manufacturing and supply, especially in the area of chemotherapy drugs. Companies that can provide aseptically prepared medicines in ready-to-administer formats and comply with national standards would be well-suited to compete. With multiple contracts available, this is an ideal entry point for both established players and small to medium enterprises looking to expand their market presence in the healthcare sector.

## Notice

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### Lot Information

BORTEZOMIB

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

CARBOPLATIN

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

CETUXIMAB

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

CISPLATIN

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

CYCLOPHOSPHAMIDE

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

CYTARABINE

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

DESFERRIOXAMINE

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

DOCETAXEL

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

DOXORUBICIN

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

EPIRUBICIN

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

FLUOROURACIL

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

GANCICLOVIR

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

GEMCITABINE

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

INFLIXIMAB

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

IRINOTECAN

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

METHOTREXATE

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

NIVOLUMAB

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

OXALIPLATIN

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

PACLITAXEL

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

PEMBROLIZUMAB

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

PERTUZUMAB

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

RITUXIMAB

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

TRASTUZUMAB SC

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

TRASTUZUMAB IV

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

VINCRISTINE

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

Aseptically Prepared Dose Banded Medicines

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

CIVAS (Centralised Intravenous Additive Service)

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

Patient Specific Chemotherapy

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

Renewal: Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Find A Tender Service |
| Latest notice | https://www.find-tender.service.gov.uk/Notice/019105-2022 |
| Notice type | Tender Notice |
| Procurement type | Framework |
| Procurement category | Goods |
| Procurement method | Open |
| Procurement method details | Open procedure |
| Tender suitability | Not specified |
| Awardee scale | SME |
| All stages | Tender, Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 13 Jul 2022 |
| Submission deadline | 14 Feb 2022 |
| Future notice date | Not specified |
| Award date | 30 Jun 2022 |
| Contract period | Not specified |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | £3,500,000,000 |
| Lots value | £3,500,000,000 |
| Awards value | Not specified |
| Contracts value | £800,000,000 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Cancelled |
| Awards status | Active |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | HEALTHTRUST EUROPE LLP (HTE) ACTING AS AGENT FOR THE UNIVERSITY HOSPITALS OF COVENTRY AND WARWICKSHIRE NHS TRUST (“UHCW”) |
| Locality | EDGBASTON, BIRMINGHAM |
| Post town | Birmingham |
| Postcode | B15 1NU |
| Country | England |
| ITL 1 | TLG West Midlands (England) |
| ITL 2 | TLG3 West Midlands |
| ITL 3 | TLG31 Birmingham |
| Local authority | Birmingham |
| Electoral ward | Edgbaston |
| Westminster constituency | Birmingham Edgbaston |
| Delivery location | Not specified |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 4 |
| Supplier names | BAXTER HEALTHCARE; QUALASEPT LTD T/A BATH ASU; QUANTUM PHARMACEUTICAL; SCIENSUS PHARMA SERVICES |

## CPV Codes

### Divisions

- 33 - Medical equipments, pharmaceuticals and personal care products
- 85 - Health and social work services

### Codes

- 33600000 - Pharmaceutical products
- 33680000 - Pharmaceutical articles
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

## Release History

- 13 Jul 2022 at 08:18 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/019105-2022
- 7 Jan 2022 at 22:45 - Tender - Tender Notice - https://www.find-tender.service.gov.uk/Notice/000565-2022

## Notice URLs

- https://healthtrusteurope.bravosolution.co.uk
- https://sid4gov.cabinetoffice.gov.uk/organisation/register

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-0308cd. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-0308cd.json.